<p>Around 11 per cent of the total <strong><a href="http://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank">Covid-19</a></strong> cases in the country have been reported in persons aged less than 20, Minister of State for Health Bharati Pravin Pawar told the Lok Sabha on Friday.</p>.<p>The minister was responding to a question on the number of children up to 18 years of age who have contracted Covid-19 as of July 2021.</p>.<p>Giving details of Covid-19 vaccines for children which are in the pipeline/trial stage, Pawar, in a written reply, said the national regulator -- CDSCO -- has granted permission to conduct clinical trials of Covid-19 vaccines in children to Bharat Biotech, Hyderabad (in age group 2 to 18) for phase-II/III of Whole-Virion Inactivated SARS-CoV-2 Vaccine and to Cadila Healthcare Ltd, Ahmedabad (in age group ≥12 yrs and above) for Phase-III clinical trial of DNA-based vaccine.</p>.<p>The outcome of these trials will depend on data emerging from the trial for the purpose of its approval and availability in the country, the minister said.</p>.<p><strong>Check out DH's latest videos:</strong></p>
<p>Around 11 per cent of the total <strong><a href="http://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank">Covid-19</a></strong> cases in the country have been reported in persons aged less than 20, Minister of State for Health Bharati Pravin Pawar told the Lok Sabha on Friday.</p>.<p>The minister was responding to a question on the number of children up to 18 years of age who have contracted Covid-19 as of July 2021.</p>.<p>Giving details of Covid-19 vaccines for children which are in the pipeline/trial stage, Pawar, in a written reply, said the national regulator -- CDSCO -- has granted permission to conduct clinical trials of Covid-19 vaccines in children to Bharat Biotech, Hyderabad (in age group 2 to 18) for phase-II/III of Whole-Virion Inactivated SARS-CoV-2 Vaccine and to Cadila Healthcare Ltd, Ahmedabad (in age group ≥12 yrs and above) for Phase-III clinical trial of DNA-based vaccine.</p>.<p>The outcome of these trials will depend on data emerging from the trial for the purpose of its approval and availability in the country, the minister said.</p>.<p><strong>Check out DH's latest videos:</strong></p>